Profile data is unavailable for this security.
About the company
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
- Revenue in USD (TTM)8.36m
- Net income in USD-297.59m
- Incorporated2015
- Employees188.00
- LocationRelay Therapeutics Inc60 Hampshire StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://relaytx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.40bn | 26.00 | -- | 7.39 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.44bn | 61.00 | -- | 16.40 | -- | 23.07 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Alvotech SA | 573.35m | 69.50m | 1.47bn | 1.01k | 22.51 | -- | 13.97 | 2.56 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.52bn | 136.00 | -- | -- | -- | 8.97 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.53bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Relay Therapeutics Inc | 8.36m | -297.59m | 1.53bn | 188.00 | -- | 2.50 | -- | 182.74 | -1.75 | -1.75 | 0.0491 | 3.52 | 0.0104 | -- | -- | 32,015.33 | -37.20 | -31.62 | -39.14 | -32.85 | -- | -- | -3,561.43 | -1,130.74 | -- | -- | 0.00 | -- | -60.83 | -- | 1.25 | -- | -24.08 | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.55bn | 123.00 | -- | 4.65 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.56bn | 60.00 | -- | 5.55 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.57bn | 186.00 | -- | 2.62 | -- | 602.39 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.57bn | 31.00 | -- | 19.52 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.58bn | 28.00 | -- | 3.26 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.60bn | 74.00 | -- | 9.54 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.61bn | 65.00 | -- | 3.38 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.62bn | 317.00 | -- | 2.97 | -- | 19.26 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Agios Pharmaceuticals Inc | 44.79m | -401.27m | 1.64bn | 486.00 | -- | 1.27 | -- | 36.54 | -6.96 | -6.96 | 0.7768 | 22.04 | 0.0282 | 0.1959 | 11.00 | 92,162.55 | -25.26 | -10.38 | -26.90 | -11.09 | 87.22 | -- | -895.86 | -768.40 | 13.39 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
Data as of Feb 13 2026. Currency figures normalised to Relay Therapeutics Inc's reporting currency: US Dollar USD
51.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Commodore Capital LPas of 30 Sep 2025 | 17.00m | 9.81% |
| Point72 Asset Management LPas of 30 Sep 2025 | 14.77m | 8.52% |
| Casdin Capital LLCas of 30 Sep 2025 | 11.34m | 6.54% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 10.48m | 6.05% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.65m | 4.99% |
| Bellevue Asset Management AGas of 30 Sep 2025 | 8.35m | 4.82% |
| Tang Capital Management LLCas of 30 Sep 2025 | 8.07m | 4.66% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 5.07m | 2.92% |
| Geode Capital Management LLCas of 30 Sep 2025 | 3.05m | 1.76% |
| Kynam Capital Management LPas of 30 Sep 2025 | 2.89m | 1.67% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
